Longeveron Inc. (LGVN), a clinical stage biotechnology company, will be participating at the 149th annual conference of the National Investment Banking Association, to be held in Fort Lauderdale, FL, September 6-7, 2023.
The company will discuss about its pipeline progress and investment strategies at the conference.
Longeveron's lead drug candidate LOMECEL-B is in Phase 2a study in Alzheimer's disease, dubbed CLEAR MIND, with topline results expected by October 2023.
A Phase 2 study of LOMECEL-B in hypoplastic left heart syndrome, dubbed ELPIS II, is ongoing, with enrollment expected to be completed by mid-2024.
A Phase 2 study of Lomecel-B in patients with aging-related frailty has been initiated and enrolment is underway in Japan.
https://www.rttnews.com/3387335/longeveron-awaits-alzheimer-s-disease-trial-data.aspx
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.